A New Golden Age for Target ID: Accessing the Novel Druggable Space with Discovery Proteomics

Pharmaceutical drug development has traditionally focused on a limited number of well-characterized biological targets, with multiple companies developing drugs around the same proteins and pathways. Competitive crowding has created a race to compress time-to-market, prioritizing development execution over novel exploration.

Luckily, innovative new drug modalities like ADCs, T cell engagers, radioligands, and protein degraders are expanding the druggable space to disease-modifying proteins once considered too challenging to reach. This is ushering a new era for target identification, opening up new areas of the proteome for therapeutic targeting.

In this webinar hosted by Oxford Global, we discuss how mass spectrometry-based discovery proteomics for target identification enables therapeutic developers to rapidly map this novel druggable space, measuring thousands of proteins and PTMs in the blood and tissue proteome with high analytical specificity. We will share how these analyses can lead developers to the most biologically interesting targets – not just the most popular – for novel discovery and greenfield development opportunities that can pave the way for new therapeutic breakthroughs.

You’ll learn about:

• Trends that have led to intense competition around a small pool of protein targets
• How innovative new drug modalities are significantly broadening the druggable space
• Why mass spectrometry-based discovery proteomics is ideally suited for the new ‘golden era’ of target identification, supporting novel discovery of drug targets in the previously undruggable realms of the proteome